肺癌治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00030093
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 206
Buy Now

【研究报告】肺癌治疗市场预计将从2022年的310.1832亿美元增长到2030年的804.9384亿美元;预计2022年至2030年复合年增长率为12.7%。
市场洞察和分析师观点:
随着肺癌病例的增加以及吸烟和吸烟习惯的增加,肺癌治疗市场规模正在扩大。英国、德国、美国和印度等国家的烟草消费。在英国,每年约有 48,000 人被诊断患有肺癌,约 35,000 人死于该疾病。吸烟是肺癌最常见的原因,其他原因包括被动吸烟和接触某些气体和化学物质。目前,德国有四分之一的男性(约 27.0%)和五分之一的女性(约 21%)经常吸烟。目前肺癌治疗的前景广阔,拥有多种药物批准、丰富的产品线以及许多正在进行的临床试验。多种肺癌疗法正处于临床开发的不同阶段;制药巨头正在努力扩大其产品线,这是肺癌治疗市场的一个重大机遇。
增长动力和挑战:
肺癌是全世界死亡的主要原因之一。如果及早诊断,这种类型的癌症可以得到更有效的治疗。因此,肺癌高危人群需要接受常规检查,以检测肺部癌变的形成情况。在全球范围内,肺癌是男性最常见的癌症,也是女性第二大常见的癌症。根据世界卫生组织 (WHO) 的数据,肺癌是全球男性和女性癌症相关死亡的主要原因。根据世界癌症研究基金会的数据,2020 年全球新增肺癌病例约 220 万例。
根据美国癌症协会对美国肺癌的估计,可能会新增约 238,340 例肺癌病例到 2023 年,其中女性人数为 120,790 人,男性人数为 117,550 人。此外,根据国家生物技术信息中心 (NCBI) 的数据,意大利每年约有 41,000 例新诊断肺癌和约 34,000 例死亡。根据澳大利亚癌症 2023 年报告,2022 年诊断出约 14,529 例新肺癌病例,其中包括 7,707 名男性和 6,822 名女性。 2022 年,近 9% 的新癌症病例被诊断出来,估计有 8,664 人死亡。土耳其卫生部提供的数据表明,土耳其每年约有 23,000 名男性和约 4,500 名女性被诊断患有肺癌。因此,全球肺癌发病率的上升促进了肺癌治疗的研发活动,进而推动了市场的增长。
自 1995 年以来,新药的价格显着上涨由于生物制剂在肿瘤学中的接受,癌症药物得到了广泛应用。在美国,每月治疗癌症的费用约为 100,000 美元。抗癌药价格全国最高;这些药物的价格比欧洲的药物贵两倍多,比世界其他地区的药物贵两到六倍。一些国家的肺癌治疗费用如下:
国家
治疗费用范围
印度
100,000–2,00,000 印度卢比(1,203.01–2,406.02 美元)
美国
25,000美元至50,000美元
尼日利亚
……5,540,000–9,000,000(721.56–1,172.2美元)
肯尼亚
KES.100,000–300,000(668.22–2,004.66美元)
加纳
GHS 80,000–2,00,000 (US$ 6,823.44–17,058.6)
土耳其
里拉 180,000–22,000 (US$ 6,512–7,959.12)
德国
€18,000–25,000 ( 19,046.5–26,453.5 美元)
许多抗癌药物的每月费用大大超过大多数家庭的收入。因此,研究人员面临着限制成本和展示价值的巨大压力。许多国家的政治不确定性和持续的经济压力引发了人们对公共卫生保健资金可持续性的担忧。在不太富裕的国家,缺乏具有成本效益的药物影响了人口的健康状况,导致平均预期寿命较低。在没有全民医疗保健和医疗保健提供者的国家,患者必须自费支付治疗费用。与药物相关的高成本限制了肿瘤药物制造商的收入,因为它们仅限于富裕人群和拥有有效保险的人群。因此,高昂的药物和手术成本阻碍了肺癌治疗市场的增长。
战略见解
报告细分和范围:
肺癌治疗市场根据治疗类型、适应症、终点进行划分用户和地理位置。肺癌治疗市场按疫苗类型分为无创疗法和微创疗法。微创细分又分为射频消融、微波消融、热消融、冷冻消融、化学消融、光动力消融等。肺癌治疗市场按适应症分为非小细胞肺癌和小细胞肺癌。按最终用户划分,市场分为医院、肿瘤诊所、研究中心等。根据地理位置,肺癌治疗市场分为北美(美国、加拿大和墨西哥)、欧洲(英国、德国、法国、意大利、西班牙、俄罗斯和欧洲其他地区)、亚太地区(中国、日本、印度、韩国、澳大利亚、东南亚和亚太地区其他地区)、中东和非洲(阿联酋、沙特阿拉伯、南非以及中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷、以及南美洲和中美洲其他地区)。
细分分析:
肺癌治疗市场按疫苗类型分为无创治疗和微创治疗。微创细分又分为射频消融、微波消融、热消融、冷冻消融、化学消融、光动力消融等。 2022年,无创治疗领域占据更大的市场份额。微创领域预计在 2022 年至 2030 年期间将录得更高的复合年增长率。放射治疗、化学治疗和靶向治疗是非侵入性肺癌治疗的主要类型。肺癌放射治疗使用高能和强大的 X 射线来消除癌细胞、控制其生长并阻止其在肺部内扩散。放射治疗在手术前后使用,以在手术前缩小肿瘤并在手术后杀死持续存在的癌细胞。在化疗中,药物用于杀死肺部新的或现有的癌细胞。化疗被认为是肺癌的重要治疗方法。根据2023年发表的《化疗统计》文章,大约2%的1期和2期患者、9%的3期患者和27%的4期患者接受化疗来治疗肺癌。
微创细分领域进一步细分为射频消融、微波消融、热消融、冷冻消融、化学消融、光动力消融等。光动力消融是一种未得到充分利用的疗法,它通过产生活性氧来选择性破坏癌细胞。这种类型的疗法已在临床和体外环境中进行了广泛的研究。已经进行了各种研究来检查光动力消融疗法与纳米颗粒联合治疗肺癌患者的疗效。
射频消融 (RFA) 是癌症患者(包括不能手术的 NSCLC 患者)最新且最有前途的治疗方法。 RFA利用热的生物效应对肿瘤造成不可逆的损伤或凝固性坏死,具有较高的可行性和安全性。近年来,越来越多的医院开始选择 RFA 而不是立体定向放射治疗 (SBRT) 作为早期诊断 NSCLC 的非手术治疗选择。因此,光动力消融治疗研究活动的增加以及对射频消融治疗的日益偏好正在推动 RFA 领域肺癌治疗市场的增长。微波消融技术是利用细针将微波传输到肝脏肿瘤中,以热量破坏癌细胞。
化学消融是将化学混合物注入静脉中,然后使用超声成像进行观察的技术。从无水乙醇、冰醋酸到表霉素,不同药物的应用和组合已经经过了很长时间的临床测试。
肺癌治疗市场,按治疗类型 - 2022 年和 2030 年
区域分析:
根据地理位置,肺癌治疗市场分为北美、欧洲、亚太地区、中东和非洲以及南美洲和中美洲。北美是全球肺癌治疗市场增长的最大贡献者。预计 2022 年至 2030 年,亚太地区肺癌治疗市场复合年增长率最高。美国肺癌治疗市场的增长主要是由肺癌病例发病率上升、产品发布和政府举措推动的。肺癌是美国第二大常见癌症。根据美国癌症协会的数据,截至 2023 年,美国约有 238,340 名成年人(117,550 名男性和 120,790 名女性)被诊断患有肺癌;此外,约有 127,070 人(男性 67,160 人,女性 59,910 人)死于该疾病。肺癌占所有癌症死亡的五分之一,使其成为美国癌症死亡的主要原因。根据同一来源,非小细胞肺癌 (NSCLC) 占所有肺癌诊断的 81%。因此,该国肺癌发病率的上升推动了美国肺癌治疗市场的增长。
公司推出的各种治疗肺癌的产品也促进了市场的增长。 2021年5月,美国FDA批准Lumakras(sotorasib)作为首个针对成人非小细胞肺癌患者的靶向治疗药物。这是首个获批用于治疗 KRAS 突变肿瘤的靶向疗法,该突变约占非小细胞肺癌 (NSCLC) 病例报告突变的 25%。 2021 年 5 月,美国 FDA 加速批准 Rybrevant (amivantamab-vmjw),这是一种针对表皮生长因子 (EGF) 和 MET 受体的双特异性抗体,用于治疗包含 EGFR 外显子 20 插入突变的局部晚期或转移性 NSCLC 成人患者。
行业发展和未来机遇:
肺癌治疗市场主要参与者的各种举措如下:
2023 年 10 月,强生公司提交了 II 类扩展适应症申请,寻求批准欧洲药品管理局 (EMA) 使用 RYBREVANT (amivantamab) 联合化疗(卡铂和培美曲塞)作为激活表皮生长因子受体的晚期非小细胞肺癌 (NSCLC) 成年患者的一线治疗( EGFR)外显子 20 插入突变。2022 年 12 月,RF Medical Co Ltd 宣布 FDA 批准其专利 MYGEN M-3004 发生器和 MYOBLATE 射频消融系统在美国商业化。这些设备用于治疗受损的肿瘤和组织。 2021年5月,强生旗下杨森制药公司宣布,美国 FDA 加速批准 RYBREVANTTM(amivantamab-vmjw)用于治疗局部晚期或转移性非肿瘤成年患者。具有 EGFR 外显子 20 插入突变的小细胞肺癌 (NSCLC)。该药物适用于在铂类化疗期间或之后出现疾病进展的患者。 RYBREVANTTM 是第一个被批准用于治疗 NSCLC 患者的全人源双特异性抗体,其靶向 EGFR 外显子 20 插入突变,这是第三种最常见的激活突变。竞争格局和主要公司:
肺癌治疗市场的一些知名企业包括美敦力公司 (Medtronic PLC)、RF Medical Co Ltd、强生公司、默克公司、太阳制药工业有限公司、Bioventus Inc、Meiji Seika Pharma Co Ltd、Advanz Pharma Corp 和 Olympus Corp。这些公司专注于新产品发布和地域扩张,以满足全球不断增长的消费者需求,并增加其专业产品组合的产品范围。他们的全球业务使他们能够为大量客户提供服务,从而促进市场扩张。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is lung cancer therapy?

The most common treatment for lung cancer includes surgery, radiotherapy, chemotherapy, and immunotherapy. Lung cancer now a days is treated by targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly target the cancerous cells. Therapies such as ablation and chemotherapy destroy healthy cells along with infected cells, which can affect the overall patient condition. Targeted therapy is designed in a way to selectively kill cancerous cells, keeping the function of healthy cells unhampered. With recent developments in medical technologies, focus on the use of targeted therapy for the treatment of lung cancer is increasing notably. Scientists are focusing on studying lung cancer cell mutations that are responsible for driving the uncontrolled growth of cancerous cells.

What are the driving and restraining factors for the lung cancer therapy market?

The increasing cases of lung cancer, and government initiatives for the screening and treatment of lung cancer bolster the lung cancer therapy market size. However, the high cost of lung cancer therapy hinders the lung cancer therapy market growth.

Who are the major players in market the lung cancer therapy market?

The lung cancer therapy market majorly consists of the players such Medtronic PLC, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Meiji Seika Pharma Co Ltd, Advanz Pharma Corp, and Olympus Corp among others.

Which segment is dominating the lung cancer therapy market?

The lung cancer therapy market is analyzed on the basis of disease indication, type, offering, technology, and end user. Based on therapy type, the lung cancer therapy market is segmented into non-invasive and minimally invasive. Minimally Invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. In 2022, the noninvasive therapy segment held a larger market share. The minimally invasive segment is expected to record a higher CAGR during 2022–2030.

The List of Companies - Lung Cancer Therapy Market

  1. Medtronic PLC
  2. RF Medical Co Ltd
  3. Johnson & Johnson
  4. Merck KGaA
  5. Sun Pharmaceutical Industries Ltd
  6. Bioventus Inc
  7. Meiji Seika Pharma Co Ltd
  8. Advanz Pharma Corp
  9. Olympus Corp

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports